Assunta Bianco

@policlinicogemelli.it

Department of Neuroscience
Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Assunta Bianco


               Download Compact PDF  
https://researchid.co/assunta_bianco

RESEARCH, TEACHING, or OTHER INTERESTS

Neurology (clinical), Neuroscience
58

Scopus Publications

1526

Scholar Citations

22

Scholar h-index

32

Scholar i10-index

Scopus Publications

  • Paramagnetic Rim Lesions in Highly Active Multiple Sclerosis at the Time of Disease Diagnosis: Prevalence Data and Clinical Implications
    Alessandra Cicia, Matteo Lucchini, Gianluca Di Fiore, Luca Ausili Cefaro, Assunta Bianco, Viviana Nociti, Vincenzo Carlomagno, Simona Gaudino, Massimiliano Mirabella
    European Journal of Neurology, 2026
    Background Paramagnetic rim lesions (PRLs) are emerging MRI biomarkers of smoldering inflammation in multiple sclerosis with prognostic relevance 1 . However, their prevalence in the early stages of the disease remains underexplored. Objective This prospective cohort study investigated the prevalence, anatomical distribution, and clinical significance of PRLs in newly diagnosed relapsing MS patients with high disease activity and explored their associations with conventional and non‐conventional MRI measures, serum neurofilament light chain (sNfL), and clinical outcomes. Methods We enrolled treatment‐naïve patients who had received an MS diagnosis in the previous 12 months. Patients underwent 3 T brain and spinal MRI including susceptibility‐weighted imaging at baseline, 6, and 12 months, along with neurological and cognitive assessments and sNfL sampling. Results The cohort consisted of 21 patients, with a mean age of 31 and median disease duration of 9 months (IQR 4–17). Median EDSS score was 1.5. All patients presented with spinal cord lesions and 38% showed Gd + lesions. PRLs were detected in 76%, with a mean of 4.9 lesions per subject. Higher PRL burden correlated with greater T2 lesion volume and cortical lesion count, higher EDSS, reduced SDMT scores, and elevated baseline sNfL. PRLs remained stable over 12 months despite treatment; two new PRLs emerged at month 12. sNfL levels were higher in patients with ≥ 4 PRLs and decreased in all during follow‐up. Conclusions Paramagnetic rim lesions (PRLs) are detectable early in RMS and correlate with a more severe clinical and radiological profile. The combined assessment of PRLs and CLs may improve disease monitoring and guide personalized treatment.
  • Wash-out duration and lymphocyte count in switching from fingolimod to ofatumumab: A case report and literature review
    Assunta Bianco, Rosellina Russo, Alessandra Cicia, Sofia Marini, Matteo Lucchini, Massimiliano Mirabella
    Journal of Neuroimmunology, 2026
  • Positioning siponimod and the post-treatment gap: the unmet needs of SPMS patients in Italian real-world practice
    Aurora Zanghì, Giovanna Borriello, Matteo Foschi, Assunta Bianco, Elisabetta Signoriello, Maria Cellerino, Paola Sofia Di Filippo, Francesco Baldisseri, Giuseppe Romano, Alessandra Cicia, Giacomo Lus, Matilde Inglese, Massimiliano Mirabella, Carlo Avolio, Emanuele D’Amico
    Therapeutic Advances in Neurological Disorders, 2026
    Background: Siponimod, a selective sphingosine-1-phosphate receptor modulator was approved for patients with Secondary progressive Multiple Sclerosis (SPMS) with ongoing disease activity. However, its real-world positioning and management after discontinuation remain challenging. Objectives: To evaluate the real-world use of siponimod in Italian real world setting, focusing on discontinuation rates, possible predictors, and post-treatment management. Methods: A retrospective, multicenter study on patients treated with siponimod across six Italian MS centers. Demographics, prior disease modifying therapy (DMTs), reasons for discontinuation, adverse events, and subsequent therapies were collected. Statistical analyses included propensity-adjusted Cox model. Results: A total cohort of 188 patients (63.8% female, median age 52 years) was enrolled, out of them 76(40.4%) discontinued siponimod, with a median treatment duration of 26 months. The main reason for discontinuation was safety concerns (72.4%), particularly persistent lymphopenia (43.6%) and recurrent infections (27.3%). Disease activity accounted for 27.6% of discontinuations. No significant demographic or clinical predictors of discontinuation were identified. After discontinuation, 49 patients (64%) started a new DMT, most commonly ocrelizumab ( n = 22) or cladribine ( n = 15), while 25 (32.9%) received no further therapy. Conclusion: High discontinuation rates, mainly due to safety, and frequent post-treatment gaps highlight the need for improved, individualized management strategies for SPMS after siponimod.
  • Adult Onset of Type 2 Familial Hemophagocytic Lymphohistiocytosis After SARS-CoV-2 Vaccination with an Unusual Neurological Onset: The Great Mimic
    Flaminia Bellisario, Assunta Bianco, Francesco D’Alo’, Chiara Passarelli, Rosellina Russo, Massimiliano Mirabella, Simona Sica, Stefan Hohaus
    Diagnostics, 2025
    Background and Clinical Significance: This case report describes a 46-year-old male with no prior comorbidities who developed progressive neurological symptoms—ataxia and diplopia—shortly after the second Comirnaty (Pfizer-BioNTech) COVID-19 vaccine dose. The aim is to highlight the diagnostic challenges of central nervous system-dominant hemophagocytic lymphohistiocytosis (HLH) and its overlap with neuroinflammatory disorders. Case Presentation: Initial MRI showed demyelinating lesions in the brain and spinal cord, suggesting acute disseminated encephalomyelitis (ADEM). The patient had only transient improvement with corticosteroids and then multiple relapses with expanding CNS lesions despite cyclophosphamide, plasmapheresis, and rituximab. After 27 months, systemic features appeared, including fever, cytopenias, elevated inflammatory markers, and splenomegaly. Bone marrow analysis revealed hemophagocytosis, fulfilling HLH-2004 criteria, with an H-score of 200 supporting secondary HLH. Given consanguinity and persistent immune activation, next-generation sequencing identified two homozygous PRF1 variants—one pathogenic (p.Arg232His) and one of uncertain significance (p.Ala91Val)—consistent with autosomal recessive familial type 2 HLH. The patient underwent matched unrelated donor hematopoietic stem cell transplantation (HSCT) 11 months after HLH diagnosis, achieving initial stabilization, but ultimately died from infectious complications in March 2025 without evidence of HLH relapse. Conclusions: This case illustrates an atypical adult-onset presentation of familial HLH manifesting primarily with recurrent neuroinflammatory symptoms that initially mimicked ADEM. The diagnostic delay reflects the challenge of recognizing CNS-dominant HLH, especially in adults and in the absence of early systemic features. The identification of biallelic PRF1 variants confirmed an underlying genetic predisposition. This is the first reported case of adult-onset familial HLH presenting predominantly with neurological symptoms following COVID-19 vaccination. The case emphasizes the need to consider genetic forms of HLH in relapsing neuroinflammatory disorders and raises the hypothesis that vaccination may unmask subclinical immune dysregulation in genetically susceptible individuals
  • IgE-mediated allergic reactions to ocrelizumab in multiple sclerosis: A retrospective cohort study
    Assunta Bianco, Arianna Aruanno, Matteo Lucchini, Alessandra Cicia, David Longhino, Marco Bisurgi, Francesca Colò, Vincenzo Carlomagno, Angela Rizzi, Alessandro Buonomo, Massimiliano Mirabella
    Multiple Sclerosis and Related Disorders, 2025
  • Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of Frailty
    Gina Ferrazzano, Roberta Fantozzi, Shalom Haggiag, Doriana Landi, Francesca Napoli, Maria Chiara Buscarinu, Leonardo Malimpensa, Assunta Bianco, Giovanna Borriello, Elena Barbuti, Fabiana Marinelli, Fabrizia Monteleone, Francesca Marchione, Nicola Falcone, Marta Altieri, Giorgio Leodori, Daniele Belvisi, Fabio Buttari, Valeria Pozzilli, Alessandra Cicia, Antonio Cortese, Francesco Sica, Anna Chiara Landi, Elisabetta Ferraro, Carlo Pozzilli, Massimiliano Mirabella, Carla Tortorella, Girolama Alessandra Marfia, Diego Centonze, Marco Salvetti, Antonella Conte
    Neurology and Therapy, 2025
    INTRODUCTION: Ofatumumab (OFA) is a highly effective therapeutic option for multiple sclerosis (MS), but real-world data on its efficacy and safety remain limited. We evaluated the real-world efficacy and safety of OFA in patients with MS and explored the predictive value of frailty. METHODS: We retrospectively collected clinical and MRI data from 12 MS centers in Central Italy, including patients who initiated OFA between April 2022 and January 2024. We assessed annualized relapse rate (ARR), clinical relapses, radiological activity, and safety. Frailty, defined as increased vulnerability due to age-related health deficits, was measured using a frailty index (FI). The study was approved by the local Ethics Committee (No. 6357). RESULTS: A total of 242 patients with MS were included (66.8% female and 33.2% male; mean age: 38.9 ± 10.3 years; disease duration: 7.7 ± 7.6 years). Of these, 95 (39.2%) were treatment-naïve, and 147 (60.8%) had switched from another therapy, mostly a first switch. The mean follow-up was 15.4 ± 5.4 months; all patients completed 12-month follow-up, and 103 completed 24 months. ARR dropped from 0.9 to 0.02 (p < 0.001). Only 4 patients (1.6%) had a clinical relapse, all within 6 months (mean time: 3.0 ± 1.8 months). Expanded Disability Status Scale (EDSS) scores remained stable (p > 0.05). MRI activity occurred in 10 patients (4.1%) at 6 months and 3 (1.2%) at 12 months; none at 24 months. Adverse events included flu-like symptoms (34.3%), injection site reactions (8.2%), and infections (18.5%). Among 239 patients assessed for frailty (mean FI: 0.06 ± 0.08), 187 were relatively fit (FI ≤ 0.10), 30 least fit, and 22 frail. FI predicted 24-month confirmed disability progression (p = 0.0068), with significant variation by frailty level (p = 0.0009). CONCLUSION: This real-world study suggests that OFA is effective and safe for MS, offering rapid disease control. Lower frailty levels suggest preferential use in patients with lower baseline disability. Further large-scale, long-term studies are needed.
  • Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian study
    Matteo Lucchini, Giovanna Borriello, Shalom Haggiag, Carolina Gabri Nicoletti, Roberta Fantozzi, Maria Chiara Buscarinu, Gina Ferrazzano, Antonio Cortese, Fabiana Marinelli, Fabrizia Monteleone, Diego Centonze, Antonella Conte, Elisabetta Ferraro, Claudio Gasperini, Girolama Alessandra Marfia, Carlo Pozzilli, Marco Salvetti, Elena Barbuti, Gianmarco Bellucci, Assunta Bianco, Vincenzo Carlomagno, Alessandro Cruciani, Laura De Giglio, Claudia Dionisi, Antonio Ianniello, Leonardo Malimpensa, Martina Nasello, Viviana Nociti, Luca Prosperini, Carla Tortorella, Massimiliano Mirabella
    Therapeutic Advances in Neurological Disorders, 2025
    Background: Cladribine (CLAD) stands as an oral disease modifying treatment (DMT) for multiple sclerosis (MS) patients, distinguished by its unique dosing regimen and mechanism of action. However, real-world data on its effectiveness remain limited, particularly regarding the clinical and therapeutical management beyond the 2-year treatment schedule. Objectives: The aim of our study was to explore the effectiveness profile of CLAD in individuals with MS (pwMS). We assessed the proportion of patients achieving no evidence of disease activity (NEDA-3) status and identified variables associated with better outcomes. Design: In this retrospective study, we collected clinical and magnetic resonance imaging (MRI) data of MS patients across 10 MS Clinics in Central Italy who started CLAD between 2018 and 2023. Methods: We evaluated the annualized relapse rate (ARR) during treatment, and the proportion of patients who experienced relapses, radiological activity, and confirmed disability progression. Additionally, we estimated the proportion of patients achieving NEDA-3 among those with a minimum follow-up of 3 months and explored baseline variables associated with NEDA status. Results: We collected data from 1094 patients with a mean follow-up of 25.1 months, of whom 79% completed the second CLAD cycle. The mean age was 37.7 years (SD 9.7), and the mean disease duration was 6.5 years, with 40.5% being treatment naïve. Despite a significant reduction of the ARR from 0.91 to 0.04 ( p &lt; 0.01) following CLAD treatment, 8.9% of patients presented at least one relapse, while 22.0% and 7.9% of patients experienced radiological activity or disability progression, respectively. Across the entire study cohort, 70.2% of patients maintained the NEDA-3 status. Younger age (HR = 0.98, p &lt; 0.001) and higher expanded disability status scale score (HR = 1.11, p = 0.049) were associated with a higher risk of not achieving the NEDA-3 status. Additionally, we included 131 patients who were older than 50 years at the time of CLAD initiation. Among the cohort, 116 patients switched to another DMT after CLAD, primarily anti-CD20 monoclonal antibodies following disease reactivation. Conclusion: This postmarketing experience confirms the effectiveness of CLAD in the treatment of pwMS, with a significant reduction in ARR and a high proportion of patients remaining free from disease activity. By contrast, some patients required an escalation strategy mainly with anti-CD20 monoclonal antibodies because of persisting disease activity.
  • An early feasibility study for neurological devices: The ARCTRAN study
    Francesco Bove, Giulia Di Lazzaro, Martina Petracca, Maria Rita Lo Monaco, Diego Ricciardi, et al.
    Neurological Sciences, 2025
    INTRODUCTION: An Early Feasibility Study (EFS) is an exploratory clinical investigation of a device to optimize its design through iterative feedback loops during early clinical experience. The ARCTRAN study is an EFS aimed at analyzing efficacy, safety and adherence to the home-rehabilitation device-based (ARC Intellicare) program compared to a paper-based exercise protocol in patients with Parkinson's disease (PD), Multiple Sclerosis (MS) and stroke. MATERIALS AND METHODS: At baseline (T0), patients of each group were randomly divided into two arms, with a 1:1 ratio: an 'interventional' group received ARC Intellicare and a 'control' group received a paper-based rehabilitation protocol, both consisting of three 60-minute sessions/week for 8 weeks. Each patient was evaluated by means of clinical scales, gait analysis and stabilometry at baseline (T0) and after the rehabilitation (T2). RESULTS: All patients (n = 90, 30 per group) showed a significant improvement in clinical scales between T0 and T2. Stroke patients showed a bigger gait improvement in the ARC Intellicare arm, measured both by clinical scales (Tinetti gait p = 0.01) and gait analysis parameters. In PD group, only gait analysis parameters recorded a significant improvement in the active arm. DISCUSSION: We demonstrate the safety of ARC Intellicare for home-based rehabilitation in patients with chronic neurological conditions, with high adherence levels. Moreover, in stroke group, it produced more significant improvements of gait compared to paper-based protocol. In the global scenario of the EFS projects promoted by the Italian Ministry of Health, this study is a starting point to conduct this type of studies in Italy.
  • Innovative multidisciplinary tool for screening bowel and bladder symptoms in multiple sclerosis
    Giampaolo Brichetto, Stefania Musco, Margherita Monti Bragadin, Erica Grange, Gianfranco Lamberti, Vincenzo Pedace, Sara Rinaldi, , Giulia Anelli, Simona Ascanelli, Raffaele Balsamo, Antonio Bertolotto, Assunta Bianco, Laura Brambilla, Filippo Cecconi, Raffaella Cerqua, Giancarlo Coghe, Antonella Conte, Francesco Corea, Antonio Cortese, Stefano De Biase, Marco Della Cava, Angela Di Girolamo, Ezio Falletto, Lauredana Ercolani, Franco Granella, Rosa Iodice, Carmela Leone, Ignazio Montisci, Roberta Motta, Carolina Nicoletti, Alessandra Oggero, Laura Pelizzari, Federica Petraglia, Maria Grazia Piscaglia, Elisabetta Pedrazzoli, Simone Pletto, Sarah Rasia, Francesco Savoca, Elisabetta Signoriello, Francesco Torresan, Ignazio Roberto Zarbo
    Neurological Sciences, 2025
  • A case report of cladribine‐induced IgG4-associated liver injury
    Marco Biolato, Assunta Bianco, Maria Cristina Giustiniani, Massimiliano Mirabella, Maurizio Pompili
    Acta Neurologica Belgica, 2024
  • Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study
    Caterina Lapucci, Jessica Frau, Eleonora Cocco, Giancarlo Coghe, Maria Petracca, Roberta Lanzillo, Vincenzo Brescia Morra, Carolina Gabri Nicoletti, Doriana Landi, Girolama Marfia, Marco Vercellino, Paola Cavalla, Assunta Bianco, Massimiliano Mirabella, Valentina Torri Clerici, Eugenia Tomas, Maria Teresa Ferrò, Paola Grossi, Agostino Nozzolillo, Lucia Moiola, Mauro Zaffaroni, Marco Ronzoni, Federica Pinardi, Giovanni Novi, Maria Cellerino, Antonio Uccelli, Matilde Inglese
    Multiple Sclerosis Journal, 2024
  • Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant?
    Assunta Bianco, Gabriele Di Sante, Francesca Colò, Valeria De Arcangelis, Alessandra Cicia, Paola Del Giacomo, Maria De Bonis, Tommaso Giuseppe Morganti, Vincenzo Carlomagno, Matteo Lucchini, Angelo Minucci, Paolo Calabresi, Massimiliano Mirabella
    International Journal of Molecular Sciences, 2024
  • COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients
    Alvino Bisecco, Federica Matrone, Marco Capobianco, Giovanna De Luca, Massimo Filippi, Franco Granella, Giacomo Lus, Girolama Alessandra Marfia, Massimiliano Mirabella, Francesco Patti, Maria Trojano, Agnese Mascolo, Massimiliano Copetti, Gioacchino Tedeschi, Antonio Gallo, Simona Malucchi, Maria Talentacci, Valentina Tomassini, Deborah Farina, Lucia Moiola, Agostino Nozzolillo, Alessandro Franceschini, Matteo Minetti, Elisabetta Signoriello, Giuseppe Romano, Mario Risi, Alessandro d’Ambrosio, Doriana Landi, Carolina Gabri Nicoletti, Assunta Bianco, Matteo Lucchini, Clara Chisari, Simona Toscano, Damiano Paolicelli, Pietro Iaffaldano, Matilde Inglese, Maria Cellerino, Paolo Bellantonio, Roberta Fantozzi, Giuseppe Salemi, Paolo Ragonese, Maura Danni, Gabriella Coniglio, Diana Ferraro, Giorgia Teresa Maniscalco, Antonella Conte, Paola Cavalla, Marika Vianello, Daniela Cargnelutti, Maurizia Gatto, Ardito Buonaventura, Alessandra Lugaresi, Maria Pia Amato, Paola Gazzola, Rosa Iodice, Ilaria Pesci, Sara Montepietra, Carlo Pozzilli, Elisabetta Ferraro, Mauro Zaffaroni, Davide Nasuelli, and
    Journal of Neurology, 2024
  • Clinically relevant increases in serum neurofilament light chain and glial fibrillary acidic protein in patients with Susac syndrome
    Domenico Plantone, Eleonora Sabatelli, Sara Locci, Mariano Marrodan, Sini M. Laakso, Farrah J. Mateen, Amalia Feresiadou, Tom Buelens, Assunta Bianco, Marcela P. Fiol, Jorge Correale, Pentti Tienari, Paolo Calabresi, Nicola De Stefano, Raffaele Iorio
    European Journal of Neurology, 2023
  • Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)
    Clara G. Chisari, Assunta Bianco, Vincenzo Brescia Morra, Massimiliano Calabrese, Fioravante Capone, Paola Cavalla, Carlotta Chiavazza, Cristoforo Comi, Maura Danni, Massimo Filippi, Pietro Iaffaldano, Roberta Lanzillo, Salvatore Lo Fermo, Alessandra Lucisano, Alessandra Lugaresi, Giacomo Lus, Gerolama Alessandra Marfia, Fabiana Marinelli, Massimiliano Mirabella, Lucia Moiola, Chiara Perin, Sabrina Realmuto, Simona Toscano, Maria Trojano, Domizia Vecchio, Francesco Patti
    Neurotherapeutics, 2023
  • New onset of Susac syndrome after mRNA COVID-19 vaccine: a case report
    Assunta Bianco, Francesca Colò, Silvia Falso, Rosellina Russo, Matteo Maria Carlà, Angelo Minucci, Gabriella Cadoni, Matteo Lucchini, Alessandra Cicia, Paolo Calabresi, Massimiliano Mirabella
    Journal of Neurology, 2023
  • CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis
    Matteo Lucchini, Valeria De Arcangelis, Geny Piro, Viviana Nociti, Assunta Bianco, Chiara De Fino, Gabriele Di Sante, Francesco Ria, Paolo Calabresi, Massimiliano Mirabella
    Molecular Neurobiology, 2023
  • A true isolated cognitive relapse in multiple sclerosis
    Valeria Pozzilli, Alessandro Cruciani, Fioravante Capone, Francesco Motolese, Mariagrazia Rossi, Fabio Pilato, Assunta Bianco, Massimiliano Mirabella, Guido Maria Giuffré, Luigi Fausto Calabria, Vincenzo Di Lazzaro
    Neurological Sciences, 2023
  • Liposome-based nanoparticles impact on regulatory and effector phenotypes of macrophages and T cells in multiple Sclerosis patients
    Maria Tredicine, Francesco Ria, Noemi Poerio, Matteo Lucchini, Assunta Bianco, Federica De Santis, Mariagrazia Valentini, Valeria De Arcangelis, Mario Rende, Anna Maria Stabile, Alessandra Pistilli, Chiara Camponeschi, Viviana Nociti, Massimiliano Mirabella, Maurizio Fraziano, Gabriele Di Sante
    Biomaterials, 2023
  • Correction to: Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study (Journal of Neurology, (2022), 269, 3, (1610-1617), 10.1007/s00415-021-10737-w)
    Alvino Bisecco, Arianna Fornasiero, Assunta Bianco, Antonio Cortese, Emanuele D’Amico, Giorgia Mataluni, Leonardo Sinisi, Daniele Spitaleri, Renato Docimo, Maria Chiara Buscarinu, Massimiliano Mirabella, Sebastiano Giuseppe Crisafulli, Aurora Zanghì, Carolina Gabri Nicoletti, Marco Salvetti, Viola Baione, Francesco Patti, Alessandra Girolama Marfia, Grazia Sibilia, Valentina Scarano, Davide Orlando, Giovanni Stabile, Gioacchino Tedeschi, Antonio Gallo
    Journal of Neurology, 2022
  • The Expanding Role of the Infectious Disease Expert in the Context of the MS Centre
    Matteo Lucchini, Paola Del Giacomo, Valeria De Arcangelis, Viviana Nociti, Assunta Bianco, Chiara De Fino, Giorgia Presicce, Alessandra Cicia, Vincenzo Carlomagno, Massimiliano Mirabella
    Journal of Personalized Medicine, 2022
  • Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study
    Bisecco Alvino, Fornasiero Arianna, Bianco Assunta, Cortese Antonio, d’Amico Emanuele, Mataluni Giorgia, Sinisi Leonardo, Spitaleri Daniele, Docimo Renato, Maria Chiara Buscarinu, Mirabella Massimiliano, Sebastiano Giuseppe Crisafulli, Zanghì Aurora, Carolina Gabri Nicoletti, Salvetti Marco, Baione Viola, Patti Francesco, Alessandra Girolama Marfia, Sibilia Grazia, Scarano Valentina, Orlando Davide, Stabile Giovanni, Tedeschi Gioacchino, Antonio Gallo
    Journal of Neurology, 2022
  • Neurosarcoidosis presenting as longitudinally extensive myelitis: Diagnostic assessment, differential diagnosis, and therapeutic approach
    Alessandra Cicia, Viviana Nociti, Assunta Bianco, Chiara De Fino, Vincenzo Carlomagno, Massimiliano Mirabella, Matteo Lucchini
    Translational Neuroscience, 2022
  • Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies
    Fioravante Capone, Matteo Lucchini, Elisabetta Ferraro, Assunta Bianco, Mariagrazia Rossi, Alessandra Cicia, Antonio Cortese, Alessandro Cruciani, Valeria De Arcangelis, Laura De Giglio, Francesco Motolese, Biagio Sancetta, Massimiliano Mirabella, Vincenzo Di Lazzaro
    Neurotherapeutics, 2022
  • Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients
    Assunta Bianco, Matteo Lucchini, Rocco Totaro, Roberta Fantozzi, Giovanna De Luca, Sonia Di Lemme, Giorgia Presicce, Luana Evangelista, Valeria Di Tommaso, Roberta Pastorino, Chiara De Fino, Valeria De Arcangelis, Diego Centonze, Massimiliano Mirabella
    Neurotherapeutics, 2021
  • The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
    Marco Biolato, Assunta Bianco, Matteo Lucchini, Antonio Gasbarrini, Massimiliano Mirabella, Antonio Grieco
    CNS Drugs, 2021
  • Defining the disease course of TNFα blockers-associated Multiple Sclerosis
    Matteo Lucchini, Guido Maria Giuffrè, Viviana Nociti, Assunta Bianco, Chiara De Fino, Francesco Antonio Losavio, Giorgia Presicce, Paolo Calabresi, Massimiliano Mirabella
    Journal of Neuroimmunology, 2021
  • Cyclophosphamide in highly aggressive Marburg-like multiple sclerosis
    Tommaso Nicoletti, Assunta Bianco, Matteo Lucchini, Simona Gaudino, Giovanni Frisullo, Massimiliano Mirabella
    Therapeutic Advances in Neurological Disorders, 2021
  • Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study
    Francesco Patti, , Clara Grazia Chisari, Claudio Solaro, Maria Donata Benedetti, Eliana Berra, Assunta Bianco, Roberto Bruno Bossio, Fabio Buttari, Letizia Castelli, Paola Cavalla, Raffaella Cerqua, Gianfranco Costantino, Claudio Gasperini, Angelica Guareschi, Domenico Ippolito, Roberta Lanzillo, Giorgia Teresa Maniscalco, Manuela Matta, Damiano Paolicelli, Loredana Petrucci, Simona Pontecorvo, Isabella Righini, Margherita Russo, Francesco Saccà, Giovanna Salamone, Elisabetta Signoriello, Gabriella Spinicci, Daniele Spitaleri, Eleonora Tavazzi, Maria Trotta, Mauro Zaffaroni, Mario Zappia
    Neurological Sciences, 2020
  • Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
    Matteo Lucchini, Assunta Bianco, Paola Del Giacomo, Chiara De Fino, Viviana Nociti, Massimiliano Mirabella
    Multiple Sclerosis and Related Disorders, 2020
  • Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: A 18-month multicentre study
    Clara Grazia Chisari, Claudio Solaro, Pasquale Annunziata, Roberto Bergamaschi, Assunta Bianco, Simona Bonavita, Vincenzo Brescia Morra, Roberto Bruno Bossio, Elisabetta Capello, Letizia Castelli, Paola Cavalla, Gianfranco Costantino, Diego Centonze, Salvatore Cottone, Maura Chiara Danni, Federica Esposito, Alberto Gajofatto, Claudio Gasperini, Angelica Guareschi, Roberta Lanzillo, Giacomo Lus, Giorgia Teresa Maniscalco, Manuela Matta, Damiano Paolicelli, Loredana Petrucci, Simona Pontecorvo, Isabella Righini, Marco Rovaris, Edoardo Sessa, Gabriella Spinicci, Daniele Spitaleri, Paola Valentino, Mauro Zaffaroni, Mario Zappia, Francesco Patti
    Journal of Neurology Neurosurgery and Psychiatry, 2020
  • Dominus effect: challenging complications of alemtuzumab-related thyroid autoimmunity
    Assunta Bianco, Tommaso Nicoletti, Emanuela Traini, Paola Del Giacomo, Valeria Del Gatto, Matteo Lucchini, Carlo A. Rota, Massimiliano Mirabella
    Journal of Endocrinological Investigation, 2020
  • Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis
    Lorenzo G. Mantovani, , Paolo Cozzolino, Paolo A. Cortesi, Francesco Patti
    Clinical Drug Investigation, 2020
  • Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients
    Assunta Bianco, Pier-Valerio Mari, Anna Rita Larici, Matteo Lucchini, Viviana Nociti, Francesco Antonio Losavio, Chiara De Fino, Giuseppe Cicchetti, Daniele Coraci, Luca Richeldi, Massimiliano Mirabella
    Multiple Sclerosis and Related Disorders, 2020
  • Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod
    Emilio Vanoli, Nicola Montano, Giuseppe De Angelis, Fabio Badilini, Massimiliano Mirabella, Simona Bonavita, Francesco Patti, Assunta Bianco, Maddalena Sparaco, Clara Chisari, Alice Laroni, Francesca Frigerio, Marta Bartezaghi, Silvia Rossi, Renato Turrini, Gianluigi Mancardi
    Journal of the Neurological Sciences, 2019
  • The predictive value of CSF multiple assay in multiple sclerosis: A single center experience
    C. De Fino, M. Lucchini, D. Lucchetti, V. Nociti, F.A. Losavio, A. Bianco, F. Colella, C. Ricciardi-Tenore, A. Sgambato, M. Mirabella
    Multiple Sclerosis and Related Disorders, 2019
  • The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray)
    Alessandro Enrico Grimaldi, Laura De Giglio, Shalom Haggiag, Assunta Bianco, Antonio Cortese, Sebastiano Giuseppe Crisafulli, Fabrizia Monteleone, Gerola Marfia, Luca Prosperini, Simonetta Galgani, Massimiliano Mirabella, Diego Centonze, Carlo Pozzilli, Letizia Castelli
    Plos One, 2019
  • No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study
    Luca Prosperini, Pietro Annovazzi, Laura Boffa, Maria Chiara Buscarinu, Antonio Gallo, Manuela Matta, Lucia Moiola, Luigina Musu, Paola Perini, Carlo Avolio, Valeria Barcella, Assunta Bianco, Deborah Farina, Elisabetta Ferraro, Simona Pontecorvo, Franco Granella, Luigi M. E. Grimaldi, Alice Laroni, Giacomo Lus, Francesco Patti, Eugenio Pucci, Matteo Pasca, Paola Sarchielli, Angelo Ghezzi, Mauro Zaffaroni, Damiano Baroncini, Fabio Buttari, Diego Centonze, Arianna Fornasiero, Marco Salvetti, Renato Docimo, Elisabetta Signoriello, Gioacchino Tedeschi, Antonio Bertolotto, Marco Capobianco, Giancarlo Comi, Eleonora Cocco, Paolo Gallo, Marco Puthenparampil, Roberta Grasso, Valeria Di Francescantonio, Maria Rosaria Rottoli, Massimiliano Mirabella, Alessandra Lugaresi, Giovanna De Luca, Maria Di Ioia, Valeria Di Tommaso, Luca Mancinelli, Giancarlo Di Battista, Ada Francia, Serena Ruggieri, Carlo Pozzilli, Erica Curti, Elena Tsantes, Barbara Palmeri, Caterina Lapicci, Giovanni Luigi Mancardi, Antonio Uccelli, Clara Chisari, Emanuele D’Amico, Elisabetta Cartechini, Anna Maria Repice, Eliana Magnani, Luca Massaccesi, Paolo Calabresi, Massimiliano Di Filippo, Maria Di Gregorio, and
    Journal of Neurology, 2018
  • Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients
    Viviana Nociti, Marco Biolato, Chiara De Fino, Assunta Bianco, Francesco Antonio Losavio, Matteo Lucchini, Giuseppe Marrone, Antonio Grieco, Massimiliano Mirabella
    Brain and Behavior, 2018
  • Fingolimod vs dimethyl fumarate in multiple sclerosis a real-world propensity score-matched study
    Luca Prosperini, Matteo Lucchini, Shalom Haggiag, Paolo Bellantonio, Assunta Bianco, Maria Chiara Buscarinu, Fabio Buttari, Diego Centonze, Antonio Cortese, Laura De Giglio, Roberta Fantozzi, Elisabetta Ferraro, Arianna Fornasiero, Ada Francia, Simonetta Galgani, Claudio Gasperini, Girolama Alessandra Marfia, Enrico Millefiorini, Viviana Nociti, Simona Pontecorvo, Carlo Pozzilli, Serena Ruggieri, Marco Salvetti, Eleonora Sgarlata, Massimiliano Mirabella
    Neurology, 2018
  • Sativex® effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients
    Massimo Santoro, Massimiliano Mirabella, Chiara De Fino, Assunta Bianco, Matteo Lucchini, Francesco Losavio, Andrea Sabino, Viviana Nociti
    Journal of the Neurological Sciences, 2017
  • Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis
    Luca Prosperini, Francesco Saccà, Cinzia Cordioli, Antonio Cortese, Fabio Buttari, Simona Pontecorvo, Assunta Bianco, Serena Ruggieri, Shalom Haggiag, Vincenzo Brescia Morra, Ruggero Capra, Diego Centonze, Giancarlo Di Battista, Elisabetta Ferraro, Ada Francia, Simonetta Galgani, Claudio Gasperini, Enrico Millefiorini, Massimiliano Mirabella, Carlo Pozzilli
    Journal of Neurology, 2017
  • Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment
    Assunta Bianco, Agata Katia Patanella, Viviana Nociti, Chiara De Fino, Matteo Lucchini, Francesco Lo Savio, Paolo Maria Rossini, Massimiliano Mirabella
    Multiple Sclerosis and Related Disorders, 2016
  • Acyclovir-related kidney injury during alemtuzumab infusion
    Assunta Bianco, Giovanni Gambaro, Paolo Maria Rossini, Massimiliano Mirabella
    Journal of Neurology, 2015
  • Moving to fingolimod from natalizumab in multiple sclerosis: The ENIGM is not solved
    Assunta Bianco, Paolo Maria Rossini, Massimiliano Mirabella
    JAMA Neurology, 2014
  • Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: The effect of previous exposure to natalizumab
    Assunta Bianco, Agata Katia Patanella, Viviana Nociti, Alessandro Marti, Giovanni Frisullo, Domenico Plantone, Chiara De Fino, Anna Fetta, Anna Paola Batocchi, Paolo Maria Rossini, Massimiliano Mirabella
    European Neurology, 2014
  • Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis
    Domenico Plantone, Alessandro Marti, Giovanni Frisullo, Raffaele Iorio, Valentina Damato, Viviana Nociti, Agata Katia Patanella, Assunta Bianco, Massimiliano Mirabella, Anna Paola Batocchi
    Journal of Neuroimmunology, 2013
  • Type 1 immune response in progressive multiple sclerosis
    Giovanni Frisullo, Domenico Plantone, Alessandro Marti, Raffaele Iorio, Valentina Damato, Viviana Nociti, Agata Katia Patanella, Assunta Bianco, Anna Paola Batocchi
    Journal of Neuroimmunology, 2012
  • CD8+ T cells in facioscapulohumeral muscular dystrophy patients with inflammatory features at muscle MRI
    Giovanni Frisullo, Roberto Frusciante, Viviana Nociti, Giorgio Tasca, Rosaria Renna, Raffaele Iorio, Agata Katia Patanella, Elisabetta Iannaccone, Alessandro Marti, Monica Rossi, Assunta Bianco, Mauro Monforte, Pietro Attilio Tonali, Massimiliano Mirabella, Anna Paola Batocchi, Enzo Ricci
    Journal of Clinical Immunology, 2011
  • Demyelinating encephalomyeloradiculitis with Balò-like lesions
    Alessandro Marti, Viviana Nociti, Giovanni Frisullo, Assunta Bianco, Mario Sabatelli, Tommaso Tartaglione, Pietro Attilio Tonali, Anna Paola Batocchi
    Journal of Neurology, 2010
  • Epstein-Barr virus antibodies in serum and cerebrospinal fluid from Multiple sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Amyotrophic Lateral Sclerosis
    V. Nociti, G. Frisullo, A. Marti, M. Luigetti, R. Iorio, A.K. Patanella, A. Bianco, P.A. Tonali, R.L. Grillo, M. Sabatelli, A.P. Batocchi
    Journal of Neuroimmunology, 2010
  • Lambert-eaton myasthenic syndrome associated with gastric schwannoma
    Agata Katia Patanella, Assunta Bianco, Francesco Federico, Anna Modoni, Pietro Attilio Tonali, Anna Paola Batocchi
    Muscle and Nerve, 2010
  • T-bet and pSTAT-1 expression in PBMC from coeliac disease patients: New markers of disease activity
    G Frisullo, V Nociti, R Iorio, A K Patanella, D Plantone, A Bianco, A Marti, G Cammarota, P A Tonali, A P Batocchi
    Clinical and Experimental Immunology, 2009
  • Increased CD4+CD25+Foxp3+ T cells in peripheral blood of celiac disease patients: Correlation with dietary treatment
    Giovanni Frisullo, Viviana Nociti, Raffaele Iorio, Agata Katia Patanella, Alessandro Marti, Bianco Assunta, Domenico Plantone, Giovanni Cammarota, Pietro Attilio Tonali, Anna Paola Batocchi
    Human Immunology, 2009
  • T-bet, pSTAT1 and pSTAT3 expression in peripheral blood mononuclear cells during pregnancy correlates with post-partum activation of multiple sclerosis
    R. Iorio, G. Frisullo, V. Nociti, K.A. Patanella, A. Bianco, A. Marti, M. Mirabella, P.A. Tonali, A.P. Batocchi
    Clinical Immunology, 2009
  • Glioblastoma in multiple sclerosis: A case report
    Giovanni Frisullo, Agata Katia Patanella, Viviana Nociti, Alessandro Cianfoni, Raffaele Iorio, Assunta Bianco, Alessandro Marti, Pietro Attilio Tonali, Anna Paola Batocchi
    Journal of Neuro Oncology, 2009
  • The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing-remitting multiple sclerosis
    Giovanni Frisullo, Massimiliano Mirabella, Francesco Angelucci, Marcella Caggiula, Roberta Morosetti, Cristina Sancricca, Agata Katia Patanella, Viviana Nociti, Raffaele Iorio, Assunta Bianco, Valentina Tomassini, Carlo Pozzilli, Pietro Attilio Tonali, Giuseppe Matarese, Anna Paola Batocchi
    Journal of Neuroimmunology, 2007
  • Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients
    Giovanni Frisullo, Viviana Nociti, Raffaele Iorio, Agata Katia Patanella, Assunta Bianco, Marcella Caggiula, Cristina Sancricca, Pietro Attilio Tonali, Massimiliano Mirabella, Anna Paola Batocchi
    Clinical Immunology, 2007

RECENT SCHOLAR PUBLICATIONS

  • Paramagnetic Rim Lesions in Highly Active Multiple Sclerosis at the Time of Disease Diagnosis: Prevalence Data and Clinical Implications
    A Cicia, M Lucchini, G Di Fiore, LA Cefaro, A Bianco, V Nociti, ...
    European Journal of Neurology 33 (3), e70573 , 2026
    2026
  • Positioning siponimod and the post-treatment gap: the unmet needs of SPMS patients in Italian real-world practice
    A Zanghì, G Borriello, M Foschi, A Bianco, E Signoriello, M Cellerino, ...
    Therapeutic Advances in Neurological Disorders 19, 17562864251399560 , 2026
    2026
  • Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian study
    M Lucchini, G Borriello, S Haggiag, CG Nicoletti, R Fantozzi, ...
    Therapeutic Advances in Neurological Disorders 18, 17562864251360047 , 2025
    2025
  • Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of Frailty
    G Ferrazzano, R Fantozzi, S Haggiag, D Landi, F Napoli, MC Buscarinu, ...
    Neurology and Therapy 14 (6), 2313-2325 , 2025
    2025
    Citations: 3
  • Adult Onset of Type 2 Familial Hemophagocytic Lymphohistiocytosis After SARS-CoV-2 Vaccination with an Unusual Neurological Onset: The Great Mimic
    F Bellisario, A Bianco, F D’Alo’, C Passarelli, R Russo, M Mirabella, ...
    Diagnostics 15 (23), 3000 , 2025
    2025
  • Wash-out duration and lymphocyte count in switching from fingolimod to ofatumumab: A case report and literature review
    A Bianco, R Russo, A Cicia, S Marini, M Lucchini, M Mirabella
    Journal of Neuroimmunology, 578808 , 2025
    2025
  • IgE-mediated allergic reactions to ocrelizumab in multiple sclerosis: A retrospective cohort study
    A Bianco, A Aruanno, M Lucchini, A Cicia, D Longhino, M Bisurgi, F Colò, ...
    Multiple Sclerosis and Related Disorders, 106826 , 2025
    2025
  • An early feasibility study for neurological devices: The ARCTRAN study
    F Bove, G Di Lazzaro, M Petracca, MR Lo Monaco, D Ricciardi, F Di Caro, ...
    Neurological Sciences 46 (10), 5221-5233 , 2025
    2025
    Citations: 2
  • Cladribine vs Dimethyl fumarate in RMS patients: a real-world propensity score-matched study
    M Lucchini, C Pozzilli, S Haggiag, L Prosperini, G Borriello, C Nicoletti, ...
    MULTIPLE SCLEROSIS JOURNAL 31 (3), 705-707 , 2025
    2025
  • Real-World Incidence and Risk Factors for IgE-Mediated Allergic Reactions to Ocrelizumab in Multiple Sclerosis: A Retrospective Single-Center Cohort Study
    A Bianco, A Cicia, M Lucchini, A Aruanno, M Bisurgi, D Longhino, ...
    MULTIPLE SCLEROSIS JOURNAL 31 (3), 914-915 , 2025
    2025
  • Exit Strategies from Siponimod in SPMS Patients: Addressing Treatment Gaps in a Real-World Setting
    E D'Amico, E Signoriello, M Inglese, M Foschi, M Mirabella, A Bianco, ...
    MULTIPLE SCLEROSIS JOURNAL 31 (3), 391-392 , 2025
    2025
  • Innovative multidisciplinary tool for screening bowel and bladder symptoms in multiple sclerosis
    S Rinaldi, A Bertolotto, A Bianco, L Brambilla, G Brichetto, G Coghe, ...
    MULTIPLE SCLEROSIS JOURNAL 31 (3), 529-529 , 2025
    2025
  • Pregnancy exposure to anti-CD20 Monoclonal Antibodies in women with Multiple Sclerosis: an Italian multi-center registry study,'CD20-PREGNANCY'
    I Gattuso, A Genchi, GA Marfia, D Landi, A Bianco, L Lorefice, MP Amato, ...
    MULTIPLE SCLEROSIS JOURNAL 31 (3), 405-407 , 2025
    2025
  • Prevalence and Phenotypic Variability of Headache in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
    C Sottani, F Cerulli, A Cicia, M Lucchini, M Mirabella, C Vollono, A Bianco
    MULTIPLE SCLEROSIS JOURNAL 31 (3), 803-803 , 2025
    2025
  • Real-World Effectiveness and Safety of Ofatumumab in Multiple Sclerosis: data from a 24-months follow-up study
    G Ferrazzano, R Fantozzi, S Haggiag, D Landi, F Napoli, MC Buscarinu, ...
    MULTIPLE SCLEROSIS JOURNAL 31 (3), 410-411 , 2025
    2025
  • Anti-Amphiphysin-IgG-seropositive paraneoplastic syndrome: a rare cause of Stiff Person Syndrome
    D Intini, S Scannicchio, V Velucci, M Gentile, A Bianco, R Vitobello, ...
    Parkinsonism & Related Disorders 134 , 2025
    2025
  • Focusing on Mithocondrial Dysfunction in Multiple Sclerosis: The Role of GDF-15 and FGF-21 as Prognostic Biomarkers (P5-1.016)
    V Carlomagno, A Cicia, A Bianco, M Lucchini, M Mirabella
    Neurology 104 (7_Supplement_1), 3778 , 2025
    2025
  • A case report of cladribine‐induced IgG4-associated liver injury
    M Biolato, A Bianco, MC Giustiniani, M Mirabella, M Pompili
    Acta Neurologica Belgica 124 (5), 1695-1697 , 2024
    2024
  • Real-World Effectiveness of Cladribine Tablets in Individuals with Multiple Sclerosis: Data from a Multi-Center Italian Study
    M Lucchini, G Borriello, S Haggiag, C Nicoletti, R Fantozzi, MC Buscarinu, ...
    MULTIPLE SCLEROSIS JOURNAL 30 (3), 376-377 , 2024
    2024
  • Iron rim lesions in newly diagnosed highly active Multiple Sclerosis patients: correlation with clinical and radiological measures
    A Cicia, G Di Fiore, M Lucchini, LA Cefaro, A Bianco, V Nociti, ...
    MULTIPLE SCLEROSIS JOURNAL 30 (3), 553-554 , 2024
    2024

MOST CITED SCHOLAR PUBLICATIONS

  • CD8 + T Cells in Facioscapulohumeral Muscular Dystrophy Patients with Inflammatory Features at Muscle MRI
    G Frisullo, R Frusciante, V Nociti, G Tasca, R Renna, R Iorio, AK Patanella, ...
    Journal of clinical immunology 31 (2), 155-166 , 2011
    2011
    Citations: 170
  • The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing–remitting multiple sclerosis
    G Frisullo, M Mirabella, F Angelucci, M Caggiula, R Morosetti, ...
    Journal of Neuroimmunology 192 (1-2), 174-183 , 2007
    2007
    Citations: 112
  • Comorbidities, cardiovascular therapies, and COVID-19 mortality: a nationwide, Italian observational study (ItaliCO)
    F Polverino, DA Stern, G Ruocco, E Balestro, M Bassetti, M Candelli, ...
    Frontiers in cardiovascular medicine 7, 585866 , 2020
    2020
    Citations: 87
  • SARS‐CoV‐2 infection and venous thromboembolism after surgery: an international prospective cohort study
    COVIDSurg Collaborative, GlobalSurg Collaborative, D Nepogodiev, ...
    Anaesthesia 77 (1), 28-39 , 2022
    2022
    Citations: 71
  • No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study
    L Prosperini, P Annovazzi, L Boffa, MC Buscarinu, A Gallo, M Matta, ...
    Journal of neurology 265 (12), 2851-2860 , 2018
    2018
    Citations: 67
  • Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis
    L Prosperini, F Saccà, C Cordioli, A Cortese, F Buttari, S Pontecorvo, ...
    Journal of neurology 264 (2), 284-294 , 2017
    2017
    Citations: 65
  • Selecting the best machine learning algorithm to support the diagnosis of Non-Alcoholic Fatty Liver Disease: A meta learner study
    P Sorino, MG Caruso, G Misciagna, C Bonfiglio, A Campanella, A Mirizzi, ...
    PLoS One 15 (10), e0240867 , 2020
    2020
    Citations: 58
  • The disease-modifying therapies of relapsing-remitting multiple sclerosis and liver injury: a narrative review
    M Biolato, A Bianco, M Lucchini, A Gasbarrini, M Mirabella, A Grieco
    CNS drugs 35 (8), 861-880 , 2021
    2021
    Citations: 56
  • Increased CD4+ CD25+ Foxp3+ T cells in peripheral blood of celiac disease patients: correlation with dietary treatment
    G Frisullo, V Nociti, R Iorio, AK Patanella, A Marti, B Assunta, D Plantone, ...
    Human immunology 70 (6), 430-435 , 2009
    2009
    Citations: 56
  • Fingolimod vs dimethyl fumarate in multiple sclerosis: a real-world propensity score-matched study
    L Prosperini, M Lucchini, S Haggiag, P Bellantonio, A Bianco, ...
    Neurology 91 (2), e153-e161 , 2018
    2018
    Citations: 54
  • Epstein-Barr virus antibodies in serum and cerebrospinal fluid from multiple sclerosis, chronic inflammatory demyelinating polyradiculoneuropathy and amyotrophic lateral sclerosis
    V Nociti, G Frisullo, A Marti, M Luigetti, R Iorio, AK Patanella, A Bianco, ...
    Journal of neuroimmunology 225 (1-2), 149-152 , 2010
    2010
    Citations: 54
  • Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis
    D Plantone, A Marti, G Frisullo, R Iorio, V Damato, V Nociti, AK Patanella, ...
    Journal of neuroimmunology 265 (1-2), 124-127 , 2013
    2013
    Citations: 52
  • Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies
    F Capone, M Lucchini, E Ferraro, A Bianco, M Rossi, A Cicia, A Cortese, ...
    Neurotherapeutics 19 (1), 325-333 , 2022
    2022
    Citations: 48
  • Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients
    V Nociti, M Biolato, C De Fino, A Bianco, FA Losavio, M Lucchini, ...
    Brain and Behavior 8 (6), e00968 , 2018
    2018
    Citations: 43
  • Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
    M Lucchini, A Bianco, P Del Giacomo, C De Fino, V Nociti, M Mirabella
    Multiple Sclerosis and Related Disorders 44, 102323 , 2020
    2020
    Citations: 41
  • Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients
    G Frisullo, V Nociti, R Iorio, AK Patanella, A Bianco, M Caggiula, ...
    Clinical Immunology 124 (3), 284-293 , 2007
    2007
    Citations: 41
  • CSF CXCL13 and chitinase 3-like-1 levels predict disease course in relapsing multiple sclerosis
    M Lucchini, V De Arcangelis, G Piro, V Nociti, A Bianco, C De Fino, ...
    Molecular Neurobiology 60 (1), 36-50 , 2023
    2023
    Citations: 40
  • Effectiveness of ocrelizumab in primary progressive multiple sclerosis: a multicenter, retrospective, real-world study (OPPORTUNITY)
    CG Chisari, A Bianco, VB Morra, M Calabrese, F Capone, P Cavalla, ...
    Neurotherapeutics 20 (6), 1696-1706 , 2023
    2023
    Citations: 33
  • T-bet, pSTAT1 and pSTAT3 expression in peripheral blood mononuclear cells during pregnancy correlates with post-partum activation of multiple sclerosis
    R Iorio, G Frisullo, V Nociti, KA Patanella, A Bianco, A Marti, M Mirabella, ...
    Clinical Immunology 131 (1), 70-83 , 2009
    2009
    Citations: 31
  • Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study
    F Patti, CG Chisari, C Solaro, MD Benedetti, E Berra, A Bianco, ...
    Neurological Sciences 41 (10), 2905-2913 , 2020
    2020
    Citations: 30